Kazia Therapeutics Annual Report 2021

DELIVERING MILESTONES IN ALMOST ANY OTHER SETTING, ONE OR TWO OF THESE MILESTONES WOULD PROVIDE THE CORNERSTONES OF AN EXTREMELY SUCCESSFUL YEAR. Dear Shareholder, It has become almost a cliché to describe each year in the young life of Kazia as transformative, but the word could hardly be more apt. In the last twelve months, our lead asset, paxalisib, has commenced a pivotal study for registration, we have completed a major financing round to the tune of AU$ 24 million in gross proceeds, we have out- licensed the legacy Cantrixil asset, we have in-licensed an extremely promising new asset, EVT801, and we have begun the process of commercialising paxalisib through a substantial partnership with Simcere Pharmaceutical in China. Kazia Therapeutics Limited 6 CEO’S REPORT